Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antidiabetic Effects on Intrahepatic Fat

NCT03068065

Non-Alcoholic Fatty Liver Disease Type2 Diabetes

COMPLETED PHASE4

Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.

NCT01956929

Insulin Resistance Prediabetic State

COMPLETED PHASE1

The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus

NCT00463502

Diabetes Mellitus, Type 2

COMPLETED PHASE4

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

NCT05729386

Healthy Volunteers

UNKNOWN PHASE1

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126

Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

160 Type 2 diabetes in our hospital will divide into 4 groups: group A (40 healthy volunteers), group B (40 patients who give basal and insulin treatment, group C（40 patients who give basal and Liraglutide treatment),group D（40 patients who give basal and metformin treatment). The age, height, weight, blood glucose, glycosylated hemoglobin A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid, blood pressure, course of disease, telomere length,telomerase activity will record respectively. And High-sensitive C-reactive protein (HsCRP), Par-4, GST,SOD,GSH-PX,ATF-6,CHOP,XBP-1 and Tumor necrosis factor-α（TNF-α） will detect as Baseline. After each group's treatment, Change from baseline of all indexes will record, Multifactor logistic regression will be analyzed the correlations between each positive indexes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GLP-1；Metformin；Telomere-telomerase System；Par-4

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

insulin

basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.

Group Type EXPERIMENTAL

Liraglutide

Intervention Type DRUG

GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months

Metformin

Intervention Type DRUG

Metformin(1500mg-2000mg/day) treatment for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide

GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months

Intervention Type DRUG

Metformin

Metformin(1500mg-2000mg/day) treatment for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Victoza Glucophage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%;
* Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);

Exclusion Criteria

* Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to insulin, islet cells, and GAD；
* Gestational diabetes;
* patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease;

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes